prostate cancer
Conditions
Interventions
Triple therapy group(ADT +Docetaxel + Darolutamide):NA
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male, > 18 years; 2. Pathologically confirmed prostate adenocarcinoma, with distant metastases proven by bone scan, MRI, CT, or PET. 3. Androgen deprivation therapy before or during darolutamide treatment; 4. Received at least one dose of docetaxel during darolutamide treatment; 5. As a real-world study, it allows subjects to receive local treatments such as surgery and radiotherapy.
Exclusion criteria
Exclusion criteria: 1. Neuroendocrine prostate cancer or small cell prostate cancer; 2. Lack of enough clinical data or lost of follow up; 3. Patients with concurrent cancers at the time of diagnosis of mPC or who have received any anti-cancer therapy for other cancers within 6 months after diagnosis of mPC, except for non-metastatic non-melanoma skin cancer or in situ or benign tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA response rate;Proportion of PSA<0.2ng/ml;PSA progression time; | — |
Countries
China
Contacts
Public ContactQi Ma
The First Affiliated Hospital of Ningbo University
Outcome results
None listed